Arch Therapeutics Receives CE Mark Approval for AC5(TM) Topical Hemostat in Europe

Stock Information for Arch Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Arch Therapeutics Inc

Arch Therapeutics Provides Year End Operational Update
Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
Arch Therapeutics Provides AC5® Commercialization Update
Arch Therapeutics Completes Financing as Bridge to Uplisting
Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care ("SAWC")
Dedicated HCPCS Billing Code for Arch Therapeutics' AC5® Advanced Wound System Now In Effect
Arch Therapeutics' AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services
Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.